REG-Tetragon Financial Group Limited: Statement re: Monthly Factsheet

Tetragon FinancialAnnouncement

Yesterday 07:00

Tetragon Financial Group Limited November 2025 Monthly Factsheet

 

LONDON,                     Dec. 31, 2025                     /PRNewswire/
-- Tetragon has released its Monthly Factsheet for November 2025.
*            Net Asset Value: $3,877m          
*            Fully Diluted                       NAV per Share: $41.85       
  
*            Share Price (TFG NA): $18.35          
*            Monthly                       NAV per Share Total Return: -0.6% 
        
*            Monthly Return on Equity: -0.2%          
*            Most Recent Quarterly Dividend: $0.11          
*            Dividend Yield: 2.4%
Please refer to important disclosures on page three of the Monthly Factsheet.

Please click below to access the Monthly Factsheet.

November 2025 Factsheet                     
(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4587535-1&h=740023214&u=https%3A%2F%2Fwww.tetragoninv.com%2Fwp-content%2Fuploads%2F2025%2F12%2Fmonthly-factsheet-nov-2025.pdf&a=November+2025+Factsheet)
          

About Tetragon:

Tetragon is a Guernsey closed-ended investment company. Its non-voting shares
are listed on Euronext in Amsterdam, a regulated market of Euronext Amsterdam
N.V., and also traded on the Specialist Fund Segment of the Main Market of the
London Stock Exchange. Our investment manager is Tetragon Financial Management
LP. Find out more at                                           
www.tetragoninv.com                               .

Tetragon's non-voting shares are subject to restrictions on ownership by U.S.
persons and are not intended for European retail investors.

Please see:                                           
https://www.tetragoninv.com/shareholders/additional-information               
               .

Tetragon Investor Relations:          
          Yuko Thomas          
                                 ir@tetragoninv.com

Press Inquiries:          
          Prosek Partners          
                                 pro-tetragon@prosek.com                      
        
          U.K. +44 20 3890 9193          
          U.S. +1 212 279 3115

This                     release does                     not              
      contain or constitute an offer to sell                     or a
solicitation of an offer to purchase securities                     in the
United States                     or any other jurisdiction. The securities
of Tetragon have not been and will not be registered under the U.S. Securities
Act of 1933 and may not be offered or sold in the United States or to U.S.
persons unless they are registered under applicable law or exempt from
registration. Tetragon does not intend to register any portion of its
securities in the United States or to conduct a public offer of securities in
the United States. In addition, Tetragon has not been and will not be
registered under the U.S. Investment Company Act of 1940, and investors will
not be entitled to the benefits of such Act. Tetragon is registered in the
public register of the Netherlands Authority for the Financial Markets under
Section 1:107 of the Financial Markets Supervision Act as a collective
investment scheme from a designated country.                               
            

 

 

 



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved